Global University Venturing

Zurich brain injury antibody spinout NovaGo has extended its strategic partnership with immunotherapy company Neurimmune by securing its support in a series A round.

Building on early development funding from TAU’s Technology Innovation Momentum Fund, Trobix Bio has spun out to commercialise an approach to overcoming antibacterial resistance.

Kao Yuan University's Gintel has created water quality monitoring systems that can provide information on 50 parameters of toxicity and recommend remedies.

SoftBank Vision Fund invested $1.46bn to take Grab's series H round, already backed by Toyota, Hyundai, Kia, Booking Holdings, Central Group, Yamaha, Ping An, Microsoft, Tokyo Century and KBank, to $4.5bn.

Genomic medicine developer Precision Biosciences plans to raise up to $100m in an upcoming IPO that could hand exits to Duke University and corporates Amgen, EMS and Baxter.

Nightstar Therapeutics, based on Oxford research, stands to receive $800m from Biogen in an acquisition deal that comes a year and a half after completing a $75m IPO.

Process management technology developer Iconpro was founded out of RWTH Aachen last year and is targeting its services at the manufacturing sector.

University of Utah’s TVC commercialisation office is to open a new incubator with Recursion, itself a Utah spinout, to provide facilities including wet lab and co-working space.

Ghent-founded indoor position technology business Pozyx has amassed more than $1.5m having recently completed the launch of its initial product range.

Fibronox spun out from University of Arizona’s College of Medicine – Tucson in 2017 to deliver Nox4-inhibiting drugs for fibrotic disorders including lung fibrosis.

GUV reporter Callum Cyrus takes an in-depth look at oncology spinouts four years after Global University Venturing first looked at the sector in detail, and finds there is much to be optimistic about.